[PDF] Top 20 Morbilidad y mortalidad en pacientes con fractura de cadera. Estudio prospectivo.

... the treatment of elderly patients with ...adults, inotuzumab ozo- gamicin also appeared to be an attractive option for pediatric patients with relapsed ALL not responding to conventional ... See full document

... with .5% blasts in bone marrow (BM), and Philadelphia chromosome (Ph)-positive ALL if ineligible for tyrosine kinase inhibitors treatment, .3 months after alloHSCT or .6 months after autologous HSCT. The study ... See full document

... Inotuzumab ozogamicin has already shown favorable results as monotherapy in R/R patients, including those status post multiple lines of salvage therapy, compared with standard ...safety profile seen ... See full document

... of potential clinical ...and treatment-related factors, which may contribute to the immunogenicity risk profile of a biotherapeutic (Koren et ...gemtuzumab ozogamicin (MYLOTARG™, ... See full document

... AlloSCT, treatment with INO should be limited to 2 cycles of induction or the fewest number of cycles required to achieve a CR/CRi (if CR/CRi not achieved after 2 cycles) [55, 79, ... See full document

... Given the poor outcomes of patients with relapsed and refractory ALL, recent research efforts have turned to immuno- therapy approaches that directly target antigens on ALL cells. These agents offer novel mechanisms of ... See full document

... Inotuzumab ozogamicin (INO) is an antibody-drug conjugate that consists of a humanized anti-CD22 monoclonal antibody linked to a cytotoxic agent cali- cheamicin which can cause double-strand DNA breaks and ... See full document

... the potential effectiveness of pridopidine in managing motor manifestations (ie, total motor ...capture potential disease-modifying ...experimental treatment were asked to provide written informed ... See full document

... Abstract: Alzheimer’s disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated ... See full document

... In summary, evolocumab is a powerful lipid-lowering drug, with an apparently large dose-dependent therapeutic range associated with a low rate of usually mild adverse events. Its efficacy seems to be evident both ... See full document

... efficacy/safety profile in the subsequent post-marketing real-life ...safety profile seemed to be consistent with what expected with IL-6 blockade and previously observed in patients treated with ...novel ... See full document

... eight with idiopathic disease, two with Behçets, and one with sarcoidosis. In this study, there was no significant difference in time to achieve remission (15/16 children achieved disease remission in the first year with ... See full document

... Future evaluations should focus on comparing the effi- cacy and safety of dupilumab against available systemic treatments in head-to-head trials. In addition, further studies observing the long-term efficacy and safety ... See full document

... alisporivir treatment groups maintained higher virologic response rates compared with those treated with pegylated IFN α and ribavirin, and the patients who received the 400 mg twice daily dose (arm 3) showed the ... See full document

... Abstract: Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently, clinical trials have focused on novel antiangiogenic agents in combination with chemotherapy or alone in women with primary and ... See full document

... In another open-label, Phase I study (SB1518-2007-002, clinicaltrials.gov identifier NCT00741871), 35 patients with relapsed/refractory lymphoid malignancies participated. One enrolled patient withdrew before receiving ... See full document

... the potential benefits of lebrikizumab in the treatment of patients with asthma not controlled with the currently available ...daily treatment with ICS therapy and at least one additional controller ... See full document

... Differently from voriconazole, isavuconazole is admin- istrated as a prodrug that is water soluble and therefore does not need the addition of cyclodextrin to IV formulations, eliminating concerns for nephrotoxicity due ... See full document

... the treatment of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis, nonradiographic spondyloarthritis, PsO, and ...safety profile similar to rheumatoid ...valid ... See full document

... The results of EXAM indicate that cabozantinib has sig- nificant activity in patients with medullary thyroid cancer, including those pretreated with cytotoxic and targeted therapies. The full extent of benefit will ... See full document